<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01094158</url>
  </required_header>
  <id_info>
    <org_study_id>Aramchol NAFLD Phase-II</org_study_id>
    <nct_id>NCT01094158</nct_id>
  </id_info>
  <brief_title>Study of Aramchol in Patients With Fatty Liver Disease or Nonalcoholic Steatohepatitis</brief_title>
  <acronym>Aramchol003</acronym>
  <official_title>A Phase II Placebo Controlled Randomised Study of Aramchol on Liver Triglyceride in Patients With Steatosis Due to NAFLD or NASH</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galmed Medical Reserch</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tel-Aviv Sourasky Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beilinson Hospital, Petach Tikva,Israel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Meir Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kaplan Hospital ,Rehovot,Israel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Soroka Hospital,Beer Sheva,Israel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hillel Yaffe Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rambam Hospital, Haifa, Israel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Lady Davis Carmel Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Holy Family Hospital, Nazareth, Israel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ziv Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Galmed Medical Reserch</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary purpose: Compare the changes in liver triglycerides concentration in the Aramchol
      versus the placebo arm following three month treatment.

      Secondary purpose: Comparing liver enzymes, markers of endothelial dysfunction, insulin
      resistance, SCD1 activity and cholesterol synthesis and lipid levels, between the Aramchol
      and the placebo arms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase II, multicenter, double blind, randomized, placebo controlled study on the effect of
      Aramchol on liver triglycerides concentration in patients with steatosis due to NAFLD or NASH

      The purpose of the study is to test whether Aramchol will reduce safely and effectively liver
      fat concentration in patients with NAFLD and NASH.

      Aramchol inhibits the liver enzyme Stearoyl Coenzyme A Desaturase (SCD). It reduces fatty
      acid synthesis while increasing fatty acid oxidation. It was shown to reduce liver fat in
      animal models with diet induced Fatty Liver. It has also marked hypocholesterolemic effects,
      mainly via upregulation of theABCA1 cholesterol transporter. It thus causes(incomplete) SCD
      inhibition while being antiatherogenic

      Primary purpose: Compare the changes in liver triglycerides concentration in the Aramchol
      versus the placebo arm following three month treatment.

      Secondary purpose: Comparing liver enzymes, markers of endothelial dysfunction, insulin
      resistance, SCD1 activity and cholesterol synthesis and lipid levels, between the Aramchol
      and the placebo arms.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The difference between initial and final liver triglyceride concentration (measured by NMRS) comparing the Aramchol and placebo treated patients.</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparing secondary variables of liver, metabolic and endothelial functions between the Aramchol and the placebo arms.</measure>
    <time_frame>3 months</time_frame>
    <description>Comparing liver enzymes, markers of endothelial dysfunction, insulin resistance, SCD1 activity and cholesterol synthesis and lipid levels, between the Aramchol and the placebo arms</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Non-Alcoholic Fatty Liver Disease</condition>
  <condition>Nonalcoholic Steatohepatitis</condition>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aramchol 300 mg daily (high dose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg daily (low dose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo and two doses will be compared. The Aramchol: placebo ratio is of 2:1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aramchol</intervention_name>
    <description>100mg/d tablets packaged in bottles given orally once a day in the morning within 10 minutes after breakfast for a total period time of 3 months</description>
    <arm_group_label>low dose</arm_group_label>
    <other_name>Arachidyl amido cholanoic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aramchol</intervention_name>
    <description>300 mg/d tablets packaged in bottles given orally once a day in the morning within 10 minutes after breakfast for a total period time of 3 months</description>
    <arm_group_label>high dose</arm_group_label>
    <other_name>Arachidyl amido cholanoic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>tablets packaged in bottles given orally once a day in the morning within approximately 10 minutes after breakfast</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with histologically proven NAFLD or NASH based on a biopsy performed during
             the preceding 18 months fulfilling the following criteria:

               -  At least 15% of hepatocytes showing steatosis,with Fibrosis of not more than
                  stage 3, with at most bridging fibrosis.

        Patients with a NAFLD activity score 0-2 will be considered to have NAFLD. Biopsies with an
        activity score of 3 or more will be considered NASH.

          -  Triglycerides concentration in the liver of 6% or more as measured by NMRS.

          -  At least two elevated serum ALT levels in the previous six months, with latest test
             within 2 months of trial.

          -  Normal or only slightly impaired synthetic liver function (serum albumin &gt;3.5gm%, INR
             0.8-1.3)

          -  Male or female aged 18-75 years.

          -  Negative pregnancy test at study entry for females of child bearing potential.

          -  Females of child bearing potential practicing reliable contraception throughout the
             study period.

          -  Signature of the written informed consent

        Exclusion Criteria:

          -  Evidence of cirrhosis on liver biopsy.

          -  Evidence of fibrosis of more than stage 3 on liver biopsy.

          -  Patient with liver disease due to acute or chronic hepatitis A, B,C, HIV, and all
             other liver diseases affecting liver function. Patients with cysts, hemangiomas, or
             similar abnormalities, are accepted.

          -  BMI &gt; 35 or &gt;130 kg body weight

          -  Any other concomitant, significant: metabolic, infectious, inflammatory, neoplastic,
             or other non-liver disease.

          -  Various concomitant diseases requiring chronic steroid administration.

          -  Use of warfarin, metformin, thiaglitazones, insulin or current steroid therapy of more
             than 3 days.

          -  Use of other investigational agents &lt; 30 days prior to the study.

          -  Pregnancy

          -  Daily alcohol intake &gt; 10gm/day.

          -  Patients with symptoms of significant mental illness. Inability to cooperate or
             communicate with the investigator, who are unlikely to comply with the study
             requirements, or who are unable to give informed consent.

          -  Performance status: WHO performance status â‰¥4.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ran Oren, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Liver &amp; Gastroenterology Department,The Tel Aviv Sourasky Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Soroka Medical Center</name>
      <address>
        <city>Beer Sheva</city>
        <zip>84101</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hillel Yaffe Medical Center</name>
      <address>
        <city>Hadera</city>
        <zip>38100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Lady Davis Carmel Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>34362</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah Ein Kerem M.C</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meir Medical Center</name>
      <address>
        <city>Kfar Saba</city>
        <zip>44281</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holy Family HOSPITAL</name>
      <address>
        <city>Nazareth</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Belinson,Rabin Medical Center</name>
      <address>
        <city>Petah Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaplan M.C</name>
      <address>
        <city>Rehovot</city>
        <zip>76100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Safed Ziv Hospital</name>
      <address>
        <city>Safed</city>
        <zip>13100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Tel Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Leikin-Frenkel A, Goldiner I, Leikin-Gobbi D, Rosenberg R, Bonen H, Litvak A, Bernheim J, Konikoff FM, Gilat T. Treatment of preestablished diet-induced fatty liver by oral fatty acid-bile acid conjugates in rodents. Eur J Gastroenterol Hepatol. 2008 Dec;20(12):1205-13. doi: 10.1097/MEG.0b013e3282fc9743.</citation>
    <PMID>18989145</PMID>
  </reference>
  <reference>
    <citation>Gilat T, Leikin-Frenkel A, Goldiner I, Juhel C, Lafont H, Gobbi D, Konikoff FM. Prevention of diet-induced fatty liver in experimental animals by the oral administration of a fatty acid bile acid conjugate (FABAC). Hepatology. 2003 Aug;38(2):436-42.</citation>
    <PMID>12883488</PMID>
  </reference>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 17, 2010</study_first_submitted>
  <study_first_submitted_qc>March 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2010</study_first_posted>
  <last_update_submitted>January 30, 2012</last_update_submitted>
  <last_update_submitted_qc>January 30, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2012</last_update_posted>
  <responsible_party>
    <name_title>Doctor Ran Oren</name_title>
    <organization>Liver unit, Department of Gastroenterology and Hepatology, Sourasky Medical Center. Tel Aviv.</organization>
  </responsible_party>
  <keyword>NAFLD</keyword>
  <keyword>NASH</keyword>
  <keyword>Fatty Liver</keyword>
  <keyword>Metabolic Syndrome</keyword>
  <keyword>Endothelial Dysfunction</keyword>
  <keyword>Insulin Resistance</keyword>
  <keyword>Liver Fat</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome X</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholic Acids</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

